CD62L Expression Level Determines the Cell Fate of Myeloid Progenitors

Scientists identified CD62L as a marker to reveal the heterogeneity within progenitors. They confirmed that CD62L-negative common myeloid progenitors (CMPs) represent “bona fide” CMPs, and CD62L-high CMPs are mostly restricted to granulocyte-monocyte progenitors potentials in mice and humans.